We also found that monocyte trafficking and immune cell activation are abnormal in tumor-bearing mice; thus, tumor-bearing mice show disrupted diurnal patterns of circulating monocytes, and administering SHP2 inhibitor during the day (when these nocturnal animals are at rest) maximizes therapeutic efficacy. The gene discussed is PTPN11; the disease is neoplasm.